SCHEMBL21708008

SCHEMBL21708008

CCOC(=O)c1csc(Nc2ccc(O)cc2)n1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 1/20 0.67
CYP1A2 P05177 1/20 0.60
CYP2C19 P33261 1/20 0.60
CA12 O43570 10/20 0.60
CA1 P00915 10/20 0.60
CA2 P00918 10/20 0.60
CA9 Q16790 10/20 0.60
EGFR P00533 1/20 0.58
SMN1; SMN2 Q16637 3/20 0.57
GAA P10253 2/20 0.57
RAB9A P51151 3/20 0.57
NPC1 O15118 2/20 0.57
MAPT P10636 4/20 0.56
MAPK1 P28482 2/20 0.56
GFER P55789 1/20 0.56
TDP1 Q9NUW8 3/20 0.55
NPSR1 Q6W5P4 2/20 0.55
KDM4E B2RXH2 1/20 0.55
LMNA P02545 1/20 0.55
HSP90AA1 P07900 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21708021 0.91 MAPT (0.68) CYP1A2CYP2C19CA12CA1CA2
SCHEMBL5041112 0.88 EGFR (0.73) KDM1ACYP1A2CYP2C19CA12CA1
SCHEMBL10464406 0.88 MAPT (0.65) CYP1A2CYP2C19CA12CA1CA2
SCHEMBL4789312 0.88 SMN1; SMN2 (0.69) CYP1A2CYP2C19CA12CA1CA2
SCHEMBL790315 0.87 MAPT (0.64) CYP1A2CYP2C19CA12CA1CA2
SCHEMBL21708010 0.87 GAA (0.64) CYP1A2CYP2C19CA12CA1CA2
SCHEMBL525606 0.87 MAOA (0.64) CYP1A2CYP2C19CA12CA1CA2
SCHEMBL3045328 0.85 CA12 (0.55) CYP1A2CYP2C19CA12CA1CA2
SCHEMBL20530863 0.85 SMN1; SMN2 (0.72) CYP1A2CYP2C19CA12CA1CA2
SCHEMBL3044989 0.85 L3MBTL1 (0.60) KDM1ACYP1A2CYP2C19EGFRSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200062719-A1 Application of Imidazopyridine Derivatives in Regenerative Medicine UNIVERSITY OF HEIDELBERG (DE) 2020-02-27 US disclosed
EP-3611256-A1 APPLICATION OF IMIDAZOPYRIDINE DERIVATIVES IN REGENERATIVE MEDICINE Universität Heidelberg (DE) 2020-02-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200062719-A1 Application of Imidazopyridine Derivatives in Regenerative Medicine DOT1L, NSD1, KDM3A KDM1A 18/4885CYP1A2 3477/4885CYP2C19 3845/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.